Sygnature Discovery Ltd, a provider of drug discovery services, has appointed Fraser McIntosh as vice president, in vivo pharmacology, and Kieron Hall as chief commercial officer, amid expansion of the company’s business. Mr McIntosh will lead Sygnature’s in vivo drug discovery operations worldwide, driving scientific and operational excellence across the company’s UK and Canada sites. His 30 years of experience spans the pharmaceutical, biotechnology and contract research organisation sectors, most recently at Evotec. Mr Hall will drive company strategy. Since 2011, Sygnature has delivered 50 novel pre-clinical and 30 clinical compounds in services for pharmaceutical and biotech companies and academic institutions in Europe and the US.
Sygnature announced the appointments on 17 and 12 February 2025.
Copyright 2025 Evernow Publishing Ltd.